Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:636405.
doi: 10.1155/2012/636405. Epub 2012 Nov 25.

Survival trends and long-term toxicity in pediatric patients with osteosarcoma

Melanie M Hagleitner  1 , Eveline S J M de Bont, D Maroeska W M Te Loo
Affiliations

Survival trends and long-term toxicity in pediatric patients with osteosarcoma

Melanie M Hagleitner et al. Sarcoma. 2012.

Abstract

Background. This study was conducted to investigate the clinical characteristics and treatment results of osteosarcoma in pediatric patients during the past 30 years. Trends in survival rates and long-term toxicity were analyzed. Procedure. 130 pediatric patients under the age of 20 years with primary localized or metastatic high-grade osteosarcoma were analyzed regarding demographic, treatment-related variables, long-term toxicity, and survival data. Results. Comparison of the different time periods of treatment showed that the 5-year OS improved from 58.6% for children diagnosed during 1979-1983 to 78.6% for those diagnosed during 2003-2008 (P = 0.13). Interestingly, the basic treatment agents including cisplatin, doxorubicin, and methotrexate remained the same. Treatment reduction due to acute toxicity was less frequent in patients treated in the last era (7.1% versus 24.1% in patients treated in 1979-1983; P = 0.04). Furthermore, late cardiac effects and secondary malignancies can become evident many years after treatment. Conclusion. We elucidate the prevalence of toxicity to therapy of patients with osteosarcoma over the past 30 years. The overall improvement in survival may in part be attributed to improved supportive care allowing regimens to be administered to best advantage with higher tolerance of chemotherapy and therefore less chemotherapy-related toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
5-year overall survival in pediatric patients with osteosarcoma over three decades.
See this image and copyright information in PMC

References

    1. Bacci G, Picci P, Ferrari S, et al. Primary chemotherap and deleyed surgery for nonmetastatic osteosarcom of the extremities: results in 164 patients preoperatively treates with high doses of methotrexate followed by cisplatin and doxorubin. Cancer. 1993;72:3227–3230. - PubMed
    1. Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M. Bone tumors in adolescents and young adults. Current Treatment Options in Oncology. 2008;9(1):67–80. - PubMed
    1. Eselgrim M, Grunert H, Kühne T, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatric Blood and Cancer. 2006;47(1):42–50. - PubMed
    1. Lewis IJ, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. Journal of Clinical Oncology. 2000;18(24):4028–4037. - PubMed
    1. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. Journal of Pediatric Hematology/Oncology. 2003;25(11):845–853. - PubMed

LinkOut - more resources